Circadian swallows Vegenics
Tuesday, 15 July, 2008
Circadian Technologies [ASX: CSR] is to acquire 100 per cent ownership of Vegenics as part of its strategy to transform Circadian from a biotech incubator to a full-scale drug development company.
Under the agreement, Circadian is to purchase the 33 per cent share owned by Vegenics co-founders the Ludwig Institute for Cancer Research and Licentia Limited.
Circadian will assume complete control of the rights to and development of Vegenics' VEGF technology.
In return, Circadian will give the Ludwig Institute and Licentia shares totalling 11 per cent ownership of the company, with more shares on offer once certain product development milestones are met.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
